海思科：获得创新药HSK39297片新适应症临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HSK39297, a small molecule drug developed for the treatment of generalized myasthenia gravis, indicating progress in its drug development pipeline [1] Group 1 - The drug HSK39297 is a self-developed treatment specifically targeting generalized myasthenia gravis [1] - The drug is characterized by a clear target, definite efficacy, and good safety profile [1] - The approval for clinical trials marks a significant milestone for the company's research and development efforts [1]